4//SEC Filing
Aunins John G. 4
Accession 0000899243-18-017198
CIK 0001609809other
Filed
Jun 18, 8:00 PM ET
Accepted
Jun 19, 5:03 PM ET
Size
7.2 KB
Accession
0000899243-18-017198
Insider Transaction Report
Form 4
Aunins John G.
CTO and EVP of Bioprocess Dev.
Transactions
- Exercise/Conversion
COMMON STOCK
2018-06-19+5,000→ 175,206 total - Exercise/Conversion
RESTRICTED STOCK UNITS
2018-06-19−5,000→ 10,000 total→ COMMON STOCK (5,000 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
- [F2]These restricted stock units have vested and settled or will vest and settle as to 25% of the restricted stock units on December 19, 2017, 25% on June 19, 2018; and 50% on December 19, 2018.
Documents
Issuer
Seres Therapeutics, Inc.
CIK 0001609809
Entity typeother
Related Parties
1- filerCIK 0001643756
Filing Metadata
- Form type
- 4
- Filed
- Jun 18, 8:00 PM ET
- Accepted
- Jun 19, 5:03 PM ET
- Size
- 7.2 KB